SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE

Core Viewpoint - A class action lawsuit has been filed against bluebird bio, Inc. regarding allegations of securities fraud and unlawful business practices [1] Group 1: Company Developments - On December 8, 2023, bluebird received FDA approval for its drug Lyfgenia (lovotibeglogene autotemcel) for treating sickle cell disease in patients aged 12 and older, but the approval included a black box warning for hematological malignancies due to two patients developing acute myeloid leukemia during clinical trials [2] - Following the announcement of the black box warning, bluebird's stock price dropped by $1.95 per share, or 40.54%, closing at $2.86 per share on the same day [2] Group 2: Legal Context - The class action lawsuit allows shareholders who purchased bluebird securities during the Class Period to request to be appointed as Lead Plaintiff by May 28, 2024 [1] - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered billions in damages for class members over its 85-year history [3]